(VCBeat) Apr. 21, 2021 -- GensKey, a leading company in pathogen detection, recently announced that it has completed an additional Series C round of financing in partnership with CPE. This round of hundreds of millions of yuan follows the ￥230 million Series C of GensKey in November 2020. 

Before CPE, the list of strategic investors of GensKey has included a number of well-known investors active in the biomedical field, such as Legend Capital, Softbank China Capital, Fortune Venture Capital, Huagai Capital, YuanBio Venture Capital, Apricottree Capital, etc.

As a top company in the infectious pathogen genetic testing industry, GensKey is the only company in the industry that has launched high-throughput testing products for pathogenic microorganisms based on second-generation sequencing and third-generation sequencing. The company is also the only enterprise in the industry that has achieved both imported and domestic sequencing platforms passing the MNGS laboratory quality assessment with high scores by the National Center for Clinical Inspection.

Pathogen detection based on the second generation of high-throughput sequencing products, GensKey has become the first choice for top first-class hospitals and third-party medical laboratories concerning pathogen detection. The pathogen detection product of GensKey based on nanopore sequencing technology has the advantages of metagenomic products against pathogens while it also can significantly improve the detection efficiency to give reports on the day of testing. Since the release of the product, it has been racing against time to provide test results for a large number of critically infected patients in time.

CPE is a leading alternative asset manager, with asset classes spanning private equity, mezzanine, and the public market. Founded in 2008 by a world-class team of investment professionals and supported by over 200 domestic and international investors, the firm uses its sector expertise to generate deal flow and drive the value creation work during the post-investment stage.